Co-founder Shailesh Kumar Davey will step into the role of Group CEO, succeeding Sridhar Vembu, who will now serve as Chief Scientist. Sridhar Vembu made the announcement via a post on social ...
CHENNAI: Sridhar Vembu has stepped down as the chief executive of Zoho Corp to focus more on the research and development of artificial intelligence products. Vembu would take up a new role as the ...
Sridhar Vembu, the founder and long-time chief executive officer of Zoho Corporation, has stepped down as CEO. He will now serve as the company’s chief scientist, focusing on research and ...
Zoho co-founder Sridhar Vembu reignited the debate over India’s traditional knowledge systems, asserting that dismissing them outright reflects arrogance, not scientific rigor. In a post on ...
Liver specialist and clinician-scientist Dr Cyriac Abby Philips, popularly known as ‘The Liver Doctor’ on social media, slammed Zoho co-founder and CEO Sridhar Vembu for supporting IIT Madras ...
Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron’s statements about its compliance with applicable rules and regulations ...
Zoho CEO Sridhar Vembu has backed IIT Madras director V Kamakoti in the cow urine controversy, claiming that modern science is waking up to its benefits. Zoho CEO Sridhar Vembu has backed IIT ...
Zoho CEO Sridhar Vembu backs IIT Madras Director Prof. V Kamakoti's claims on the medicinal properties of cow urine or gomutra. In a post on the social media platform X, Vembu wrote, "This nation ...
SAN FRANCISCO — Just over 20 years ago, the people of California voted to spend billions of dollars on an exciting new idea to remake medicine … ...
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities ...
Fianlimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Lymphoma. According to GlobalData, Phase I drugs for Lymphoma have a 66% phase transition success rate ...
Facilities for Regeneron Canada in thriving Mississauga/GTA biotech hub signal its growth and readiness to bring more of its life-transforming innovative medicines for serious diseases to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback